Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study.

Eur J Nucl Med Mol ImagingJun 19, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Claudia Leslie, Zeyad Al-Ogaili, Leone Oh et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase I trial evaluated the safety and maximum tolerated dose (MTD) of capecitabine combined with Lutetium-177-PSMA I&T (Lu-PSMA) in 12 men with metastatic castration-resistant prostate cancer (mCRPC). The MTD was established at 1000 mg/m², with a PSA-50 response rate of 50% and a PSA-progression free survival of 4.7 months.

Key findings

  • The maximum tolerated dose of capecitabine was established at 1000 mg/m².
  • The PSA-50 response rate was 50% across dose levels.
  • PSA-progression free survival was 4.7 months (95% CI 2.3-21.6).
  • Common treatment-related adverse events included nausea, fatigue, and diarrhoea.

Why it matters

The combination of capecitabine and Lu-PSMA may enhance treatment options for patients with heavily pre-treated mCRPC, potentially improving therapeutic outcomes in this challenging population.

Source

PubMed · PMID 42315637Free full text on PubMed Central

Published in Eur J Nucl Med Mol Imaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.